HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Effect of Cornea Preservation Time on Success of Descemet Stripping Automated Endothelial Keratoplasty: A Randomized Clinical Trial.

AbstractImportance:
Demonstrating that success of Descemet stripping automated endothelial keratoplasty is similar across donor cornea preservation times (PTs) could increase the donor pool.
Objective:
To determine whether the 3-year rate of graft success using corneal donor tissue preserved 8 to 14 days is noninferior to that of donor tissue preserved 7 days or less.
Design, Setting, and Participants:
A multicenter, double-masked, randomized noninferiority clinical trial was conducted from April 16, 2012, to June 5, 2017, at 40 clinical sites (70 surgeons) in the United States, with donor corneas provided by 23 US eye banks. A total of 1090 individuals (1330 study eyes) underwent Descemet stripping automated endothelial keratoplasty (1255 eyes [94.4%] for Fuchs endothelial corneal dystrophy).
Interventions:
Descemet stripping automated endothelial keratoplasty with random assignment of a donor cornea with a PT of 7 days or less (0-7d PT) or 8 to 14 days (8-14d PT).
Main Outcomes and Measures:
Graft success at 3 years.
Results:
Of the 1090 participants (1330 study eyes; 60.2% women and 39.8% men; median age at enrollment, 70 years [range, 42-90 years]), the 3-year cumulative probability of graft success was 95.3% (95% CI, 93.6%-96.9%) in the 0-7d PT group and 92.1% (95% CI, 89.9%-94.2%) in the 8-14d PT group (difference, 3.2%). The upper limit of the 1-sided 95% CI on the difference was 5.4%, exceeding the prespecified noninferiority limit of 4%. The difference was mostly owing to more primary donor failures in the 8-14d PT group, with the conditional probability of failure after the first month being 2.4% in the 0-7d PT group and 3.1% in the 8-14d PT group. In preplanned secondary analyses, longer PT was associated with a lower rate of graft success (unadjusted hazard ratio for graft failure per additional day of PT, 1.10; 95% CI, 1.03-1.18; P = .008 [PT analyzed as days]), with success rates of 96.5% (95% CI, 92.3%-98.4%) for PT of 4 days or less, 94.9% (95% CI, 92.5%-96.6%) for PT of 5 to 7 days, 93.8% (95% CI, 91.0%-95.8%) for PT of 8 to 11 days, and 89.3% (95% CI, 84.4%-92.7%) for PT of 12 to 14 days (P = .01 [PT analyzed as categorical variable]).
Conclusions and Relevance:
The 3-year success rate in eyes undergoing Descemet stripping automated endothelial keratoplasty was high irrespective of PT. However, the study was unable to conclude that the success rate with donor corneas preserved 8 to 14 days was similar to that of corneas preserved 7 days or less with respect to the prespecified noninferiority limit. Although longer PT was associated with a lower success rate, the difference in rates was small when PT was less than 12 days.
AuthorsGeorge O Rosenwasser, Loretta B Szczotka-Flynn, Allison R Ayala, Wendi Liang, Anthony J Aldave, Steven P Dunn, Tyrone McCall, Lisa C Navarro, Sudeep Pramanik, Kevin W Ross, R Doyle Stulting, Mark A Terry, Elmer Y Tu, David D Verdier, Craig Kollman, Robin L Gal, Roy W Beck, Jonathan H Lass, Cornea Preservation Time Study Group
JournalJAMA ophthalmology (JAMA Ophthalmol) Vol. 135 Issue 12 Pg. 1401-1409 (12 01 2017) ISSN: 2168-6173 [Electronic] United States
PMID29127431 (Publication Type: Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, N.I.H., Extramural)
Topics
  • Adult
  • Aged
  • Aged, 80 and over
  • Cell Count
  • Cornea
  • Corneal Endothelial Cell Loss (physiopathology)
  • Cryopreservation (methods)
  • Descemet Stripping Endothelial Keratoplasty (methods)
  • Double-Blind Method
  • Endothelium, Corneal (pathology)
  • Eye Banks
  • Female
  • Fuchs' Endothelial Dystrophy (physiopathology, surgery)
  • Graft Survival (physiology)
  • Humans
  • Male
  • Middle Aged
  • Organ Preservation (methods)
  • Prospective Studies
  • Time Factors
  • Tissue Donors

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: